Business
New data shows higher efficacy rate for Pfizer and BioNTech coronavirus vaccine candidate // Motley Fool Australia
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
On Wednesday morning, Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) presented new data from a final efficacy analysis on their BNT162b2 vaccine candidate, and the news was very good.
In a joint press release, the 2 partners said the vaccine met all of its primary efficacy endpoints. Better still, it had an efficacy rate of 95% in participants both with and without prior coronavirus infection (mild or severe). Also, the vaccine’s efficacy was consistent across key demographics such as age, gender, and ethnicity. No serious safety concerns were reported.
That rate, meanwhile, is higher than the 90%-plus demonstrated in the…
-
General8 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News15 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business16 hours agoBell Potter names the best ASX shares to buy in October
-
Noosa News21 hours ago28 years later: Grim reality for single house hunters revealed